Frequent plasma cell hepatitis during telaprevir-based triple therapy for hepatitis C after liver transplantation  by Ikegami, Toru et al.
Letters to the Editor
Open access uFrequent plasma cell hepatitis during telaprevir-based
triple therapy for hepatitis C after liver transplantationTo the Editor:
We recently read the article by Coilly et al. [1], who used protease
inhibitors to treat recurrent hepatitis C after liver transplanta-
tion. They described that the side effects, including severe infec-
tion and anemia, frequently led to treatment discontinuation or
signiﬁcant dose reduction. They also reported a low sustained
viral response (SVR) rate to their telaprevir-based treatment
[1]. In our patients, plasma cell hepatitis (PCH) was a frequent
complication. We describe our experience of telaprevir-based
therapy for hepatitis C after liver transplantation, with special
references to PCH.
We treated 9 patients with recurrent hepatitis C (genotype
1b) after living donor liver transplantation. The doses of telapre-
vir, pegylated interferon alpha 2b (PegIFNa2b) and ribavirin were
1500 mg/day, 1.5 lg/week, and 200–800 mg/day, respectively.
After starting telaprevir, the cyclosporine A (CsA) dose was
reduced by one-quarter to one-half from the maintenance dose
[2]. CsA level was monitored 2 times a week during the introduc-
tion and completion phase of telaprevir and on a biweekly basis
during other periods. One patient discontinued treatment
because of viral breakthrough. Thus, rapid viral response (RVR),
EVR, end-of-treatment response (ETR) and SVR12 were 33.3% (3/
9), 88.9% (8/9), 88.9% (8/9), 88.9% (8/9), respectively.
Anemia requiring ribavirin dose reductions was observed in
55.5% (5/9) of patients, and red blood cell transfusion was per-
formed in 44.4% (4/9) of patients. None of the patients experi-
enced infections. However, 33.3% (3/9) of patients developed
PCH during or after telaprevir-based triple therapy (Table 1). Cri-
teria for PCH followed those established from recent reports [3–
5]. Histological features of PCH are centrilobular and portal
necrosis and a prominent (>30%) plasma cell aggregation [3].
Because only 6.7% (7/105) of the patients who received dual ther-
apy using PegIFN and ribavirin developed PCH, the frequency of
PCH was signiﬁcantly higher (p = 0.007) in the patients with tri-
ple therapy. In all the patients receiving triple therapy, pre-treat-
ment graft biopsies were obtained and ruled out for PCH and
acute cellular rejection (ACR).
Case #1 had increased liver enzymes at week 21 and was trea-
ted with PegIFN-a2b and ribavirin after completing 12 weeks of
telaprevir. Liver biopsy showed plasma cell aggregations around
the portal triads with lymphocyte inﬁltration, bile duct injury,
and endotheliitis, suggesting a combination of PCH and ACR. Peg-
IFN-a2b and ribavirin were discontinued. The patient received a
steroid pulse, 2000 mg/day mycophenolate mofetil (MMF), and
the CsA dose level was increased to 150–250 ng/ml. The steroid
pulse consisted of 1 g of methylprednisolone, followed by taper-
ing from 200 mg to 40 mg over 5 days, and was then switched to
20 mg/day of oral prednisolone. The liver enzymes promptly sta-
bilized and hepatitis C RNA remained negative, resulting in SVR12.Journal of Hepatology
nder CC BY-NC-ND license.Case #2 had increased liver enzymes at 31 weeks after com-
pleting triple therapy with ETR. Because a biopsy showed moder-
ate PCH, the patient was treated similarly to Case #1. The
outcomes were satisfactory, with normalization of liver enzymes
and SVR12.
Cases #3 and #4 had increased liver enzymes during PegIFN-
a2b and ribavirin therapy. Because biopsies showed mild PCH
and only a short time had elapsed after completing telaprevir,
these patients were prescribed 5 mg/day of oral prednisolone,
with satisfactory outcomes with SVR12.
PCH is characterized by the inﬁltration of plasma cells around
the portal triads, without apparent bile duct injury or endotheli-
itis. PCH was also referred to as de novo autoimmune hepatitis
after liver transplantation [4]. However, Levitsky et al. [5]
recently proposed the term interferon-induced graft dysfunction
(IGD) for interferon-induced liver graft damage pathologically
characterized by PCH, ACR, chronic rejection, or a combination
of these. One of their most important ﬁndings was the poor sur-
vival of grafts with IGD and SVR, even compared with grafts with-
out SVR. PCH, a common feature of IGD, is a serious complication
during or after interferon-based treatment for hepatitis C after
liver transplantation.
Levitsky et al. [5] reported that no prior interferon treatment,
the use of PegIFNa-2a, and features consistent with PCH in pre-
treatment liver biopsy were risk factors for PCH. However, Fiel
et al. [5] reported that 80% of patients with PCH had a recent low-
ering of their immunosuppression protocol. Kugelmas et al. [6]
reported that the clearance of hepatitis C virus improved hepatic
microsomal function, resulting in lower immunosuppression lev-
els [6], and that the mean decrease in the calcineurin inhibitor
level after viral clearance was 32% in responders and <1% in
non-responders. In fact, in Cases #3 and #4 the CsA level
declined spontaneously, by 50–60%, after viral clearance, which
probably caused PCH. However, the CsA levels were stable
(100–150 ng/ml) in Cases #1 and #2. It is likely that the loss of
the therapeutic target increased the sensitivity of the host’s
immune system to the transplanted graft [3]. In triple therapy
including telaprevir, which has potent viral clearance activity
and strong interference with calcineurin inhibitor metabolism,
there might be more chances to have interferon induced PCH
and IGD.
Although the accumulation of more cases is essential, we
wish to highlight the possibility of PCH in patients treated
with protease inhibitors for hepatitis C after liver transplanta-
tion. Because of the potential severity of PCH, close monitor-
ing and careful adjustment of the CsA level is necessary at
the start of treatment and after viral clearance. Hepatologists
should be aware of this complication, and its diagnosis and
treatment.2014 vol. 60 j 894–901
Table 1. Characteristics of the cases with plasma cell hepatitis.
Case # #1 #2 #3
Age, sex 52 M 64 F 55 F
HCV genotype 1b 1b 1b
Recipient/donor rs8099917 TT/TT TG/TG TT/TT
Outcome of previous treatment Relapsed Relapsed No respond
PegIFNα2b (μg/kg/wk) 1.5 1.5 1.5
Telaprevir (mg/d) 1500 1500 1500
Ribavirin (mg/d) 400 400 200
HCV-RNA at induction (log IU/L) 6.4 5.7 6.7
Negative HCV-RNA (wk) 5 4 4
Pre-treatment graft biopsy CH-C, G2S1 CH-C, G2S1 CH-C, G2S1
Immunosuppression regimen CsA + MMF CsA + MMF CsA
CsA trough level (ng/ml)
Before induction 102 125 160
1-12 wk 102 ± 41 128 ± 19 108 ± 24
13-24 wk 125 ± 34 110 ± 16 53 ± 9
25 wk - 153 ± 14 177 ± 62 86 ± 29
Onset of PCH (wk) 21 31 14
AST (IU/L) 168 214 113
ALT (IU/L) 161 127 97
γGTP (IU/L) 158 90 150
Total bilirubin (mg/dl) 1.3 0.8 0.8
Pathology PCH, moderate
ACR, moderate
PCH, moderate PCH, mild
Treatment Discontinue IFN
Steroid pulse
Increase CsA
Add MMF
Steroid pulse
Increase CsA
Add MMF
Increase CsA
Add steroid
Treatment response Good Good Good
One month after treatment (wk) 25 35 18
AST (IU/L) 16 19 34
ALT (IU/L) 10 9 28
γGTP (IU/L) 29 45 85
Total bilirubin (mg/dl) 1.2 1.1 0.6
HCV RNA Negative Negative Negative
Maintenance immunosuppression CsA + MMF + steroid CsA + MMF + steroid CsA + steroid
Anti-viral treatment outcome EVR, SVR12 EVR, SVR12 RVR, SVR12
M, male; F, female; HCV, hepatitis C virus; CH-C, chronic hepatitis C; G, grade; S, stage; PegIFN, pegylated interferon; CsA, cyclosporine A; MMF, mycophenolate mofetil;
PCH, plasma cell hepatitis; ALT, alanine aminotransferase; AST, aspartate aminotransferase; cGTP, gamma-glutamyl transpeptidase; ACR, acute cellular rejection; IFN,
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rejection. Liver Transpl 2003;9:1159–1165.Reply to: ‘‘Frequent plasma cell hepatitis during telaprevir-based
triple therapy for hepatitis C after liver transplantation’’
To the Editor:
We much appreciate Dr Ikegami and colleagues’ comments on
our study on the use of a ﬁrst generation protease inhibitor-based
regimen to treat hepatitis C (HCV) recurrence after liver
transplantation (LT) [1]. One comment concerned the lack of
occurrence of plasma cell hepatitis (PHC) in our series of 37
patients. Dr Ikegami reported on 9 patients treated with telapre-
vir (TVR), peginterferon a2b (PegIFN) and ribavirin (RBV) in a
context of HCV recurrence after living donor LT. PHC occurred
in 33.3% of patients (3/9) during triple therapy, compared with
6.7% (7/105) during standard PegIFN/RBV. We have developed
some arguments to explain the difference between these two
different ﬁndings.
A low immunosuppressive regimen is a risk factor for the
development of PCH [2]. All patients in Dr Ikegami’s letter
received cyclosporine (CsA) ± mycophenolate mofetil (MMF).
Data concerning targeted trough blood concentrations (TBC) of
CsA, and the delay between triple therapy and LT, were lacking.
All PHC cases reported by Dr Ikegami occurred after the discon-
tinuation of TVR (weeks 21, 31, and 12). Despite biweekly moni-
toring, the mean CsA TBC in patient 3 was low after week 12
(from 53 to 86 ng/ml). Drug-drug interactions between PI and
calcineurin inhibitors have always been the main challenge when
using PI after LT. In the ﬁrst instance, we focused on the PI initi-
ation period to demonstrate its feasibility in terms of practical
management [3]. We also looked carefully at the time of PI dis-
continuation. In our study, TBC were monitored daily and CsA
doses were also adjusted daily to reach the target range. It was
necessary to increase the CsA doses by 47% after TVR discontinu-
ation [1]. In this context, HCV clearance might have an impact on
PHC occurrence with triple therapy, but drug-drug interactions
are more likely to be responsible for the excess risk found by Ike-
gami et al.
One observation in Dr Ikegami’s letter was particularly sur-
prising, and concerned the favorable outcome of PHC in all
patients. This contrasted with the usually poor prognosis of
PHC in a context of HCV recurrence. According to Fiel et al.,
patients who were not treated or were receiving corticosteroids
had a negative outcome. Cirrhosis was seen to develop in 60%
of patients (4). According to Dr Ikegami, patients 1 and 2 were
treated with steroid pulses and an increase in or addition of
mycophenolate mofetil (MMF). For patient 1, we could hypothe-
size that acute cellular rejection (ACR) justiﬁed such a treatment.
And as for patient 3, MMF and low-dose corticosteroids (5 mg)
were added to CsA.
The prevalence of PHC may vary, depending on the diagnosis
criteria applied. Most studies on PHC have considered that this
diagnosis is based on three criteria: (1) abnormality of liver tests,
(2) increased levels of immunoglobulin G and/or speciﬁc anti-
bodies of auto-immune hepatitis, (3) compatible histological fea-
tures. Dr Ikegami does not mention any serological data.
Furthermore, we have some concerns about the histological ﬁnd-
ings. The authors considered that the diagnosis was based on the
presence of centrilobular and portal necrosis and a prominent
(>30%) plasma cell (PC) aggregation, as previously described by
Fiel et al. [4]. In patient 1, PHC was associated with ACR. The dif-
ferential diagnosis between these entities can be difﬁcult. In
severe ACR, a severe portal necro-inﬂammatory activity may
mimic hepatitis. The inﬁltrate may be made up of PC, but with-
out proper PCH. In order to clarify the histological features of
PCH, we recently reported on a scoring system based on centrilob-
ular changes such as necro-inﬂammatory activity (NIA) and the
centrilobular PC ratio. The positive predictive value of the associ-
ation of severe centrilobular NIA and a PC ratio of up to 30% was
>90% [5]. In fact, we currently use these criteria to diagnose PCH.
To conclude, we agree with Dr Ikegami that PCH is a potential
complication of a TVR-based antiviral regimen. For as long as an
interferon-based regimen is used after LT, hepatologists should
be alert to possibilities of PHC occurrence. Close monitoring of
drug-drug interactions is warranted, particularly soon after PI
initiation and also at the time of PI discontinuation. We also think
that using stringent criteria based on serological markers and
histological features is crucial to preventing a misdiagnosis of
PHC.
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